Medicines planning
48 results
Applied filters
Good governance when implementing natalizumab biosimilar
11 December 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
Using our annual medicines planning publication, Prescribing Outlook
28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Costing Clinical Trials of ATIMPs using the NIHR iCT - Advice for Pharmacy Sites
12 July 2022Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.
National Homecare Medicines Committee (NHMC) Homecare Service Proposal (HSP) Form
25 November 2021The Homecare Service Proposal (HSP) Form is to be completed by pharmaceutical manufacturers where there are new homecare medicines services or where there are changes…
Annual medicines planning
Our annual Prescribing Outlook outputs support planning, implementation and budget planning for medicines every year.
Biosimilars
Regularly updated material to support the introduction of aflibercept, golimumab, ranibizumab, ustekinumab and other biosimilars of interest.
Planning
We support organisations with the planned introduction of medicines. We create annual review products as well as ongoing updates to keep you informed.
National Homecare Medicines Committee (NHMC) Engagement with Manufacturers Advice
4 August 2020The National Pharmaceutical Supply Group (NPSG) currently advises against participation in advisory boards sponsored by Manufacturers (Marketing Authorisation Holders). This NHMC paper supports this advice…